drugset / Trial / NCT00161928

Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants

NCT00161928

Phase 3 Completed 330 enrolled Pfizer
RandomizedParallel-groupOpen-labelPrevention

Summary

The primary aim of the study is to show that NeisVac-C does not influence the seroconversion rates induced by hepatitis B (Hep B), inactivated polio (IPV) and acellular pertussis (aP) vaccines in infants.

Timeline

Start
2002-04
Primary completion
Completion
2003-01

Drugs

EvaluationDrugModalityDoseRoute
Subject NeisVac-C Vaccine